AJMC Staff

Coverage of our peer-reviewed research in the healthcare and mainstream press.

The first treatment for Merkel cell carcinoma, a rare form of skin cancer, has been approved to treat adults and pediatric patients 12 years or older. The drug is also under consideration through Priority Review for treatment of patients with urothelial carcinoma.

Using patient-reported outcomes and data on healthcare utilization, researchers from the Yale School of Medicine have been able to compare the health burden of asthma—COPD overlap syndrome with asthma or chronic obstructive pulmonary disease (COPD) alone.

The FDA has issued a warning for Viberzi that patients who do not have a gallbladder have an increased risk of developing serious pancreatitis.

The study found a "dose effect" in the elderly women who took statins to treat cholesterol.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Pembrolizumab (Keytruda) received an accelerated approval for adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after at least 3 lines of therapy.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The current bill faces opposition from groups as varied as the American Medical Association and the AARP.

First-line pembrolizumab every 3 weeks followed by second-line ipilimumab, and first-line nivolumab followed by second-line ipilimumab are cost-effective strategies in patients with advanced melanoma expressing wild-type BRAF.

A landmark reimbursement decision from Medicare, and news in diabetes prevention.

A new clinical pathways program at the Cancer Treatment Centers of America will help inform treatment by seamlessly integrating into the physician’s electronic health record.